Copyright
©2011 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 7, 2011; 17(9): 1174-1179
Published online Mar 7, 2011. doi: 10.3748/wjg.v17.i9.1174
Published online Mar 7, 2011. doi: 10.3748/wjg.v17.i9.1174
Figure 2 Decreasing rate of the modified perianal Crohn’s disease activity index score after surgery in regards to infliximab.
The squares represent the median value and the circles represent range plots. The rate of reduction in modified perianal Crohn's disease activity index (mPDAI) score from baseline was significantly greater in patients with infliximab (IFX) -50.0% (0%-90%) - than in those without IFX -28.6% (0%-60%); (P = 0.003).
- Citation: Uchino M, Ikeuchi H, Bando T, Matsuoka H, Takesue Y, Takahashi Y, Matsumoto T, Tomita N. Long-term efficacy of infliximab maintenance therapy for perianal Crohn’s disease. World J Gastroenterol 2011; 17(9): 1174-1179
- URL: https://www.wjgnet.com/1007-9327/full/v17/i9/1174.htm
- DOI: https://dx.doi.org/10.3748/wjg.v17.i9.1174